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1Abstract
Understanding the biological insights hidden in the vast amount of data collected,
while investigating a disease, is the main goal for collecting such data in the first place.
Changes in the gene expression or the function of proteins are important components in
progression of a disease and is a key to understanding the disease mechanism. However,
more often than not, the causes of such changes are not easily identified. In many cases,
genetic variants may cause some of the observed gene expression changes. In this thesis, we
focus on identifying the variants that significantly alter gene expression for an individual by
integrating genetic variant data, gene expression data, as well as a priori knowledge about
gene-gene interaction networks from multiple databases. Here we show that one can use
variants that change gene expression to identify subgroups of patients with significantly
diﬀerent survival profiles. The method is validated on four diﬀerent cancer types (renal,
lung, colorectal cancer and leukemia) from the TCGA database. The results show that
this method is able to identify variants that significantly aﬀect the gene expression (and in
turn the phenotype), as well as identify disease sub-types that are biologically meaningful
as validated by survival and pathway analysis.
2Chapter 1
INTRODUCTION
Understanding the biological insights hidden in the vast amount of data collected,
while investigating a disease, is the main goal for collecting such data in the first place. The
advent of microarrays and more recently next generation sequencing make it much easier
to collect diﬀerent types of information from a variety of angles about the same sample at
the same time. Examples of such information include: DNA changes such as single point
mutations or copy number variations, DNA methylation, alternative splicing, microRNA
expression, post-translational modifications, etc. Even though we have the ability to collect
such rich data, analyzing it in order to completely understand the investigated phenotype is
still an open challenge.
Gene expression, as the most common type of data collected, can identify the impor-
tant changes between a disease state and a normal state. However, more often than not, the
causes of such changes are not easy to identify. Other types of data, such as single nucleotide
polymorphism (SNP), methylation, and copy number variation (CNV) can complement the
gene expression data [16, 18, 38, 74]. It is now accepted that the changes in the system are
not likely to be captured completely in any one type of data [39, 45]. This is particularly
true for complex diseases, such as cancer, which involve many phenomena that aﬀect many
levels [64, 91]. More information can be obtained if diﬀerent types of data were analyzed
together, thus the integration of multiple types of data has become a very important problem
to solve [78, 79, 80, 81, 82, 83, 84].
Data integration methods can be divided into two main categories: multi-stage anal-
ysis and meta-dimensional analysis [64]. In multi-staged methods, diﬀerent types of data are
3integrated one after another in sequential steps [1, 10, 65, 69, 90]. In meta-dimensional meth-
ods all types of data are integrated simultaneously to model the complex phenotype [24, 61].
The analysis results, obtained from both categories, have fewer false positives compared to
using only one data type, especially if the diﬀerent data types cover diﬀerent levels of regu-
lation in the system (e.g. genetic, genomic, proteomic etc). The method introduced in this
thesis, belongs to the meta-dimensional category since it simultaneously integrates variants
and gene expression data to identify disease subtypes.
Diﬀerent approaches have been proposed to identify variants that cause changes in
gene expression levels [26, 85, 93]. Many of the proposed approaches, mentioned in [85], also
integrate other types of information along with mutation and gene expression (e.g. copy
number variation (CNV) data, methylation data) to predict the eﬀect of presence of each
variant on the expression of its host gene [5, 6, 13, 19, 85]. Furthermore, some methods use
a priori knowledge about the network of interactions between genes because a given variant
may change the expression of a set of genes rather than a single gene [3, 23]. In this thesis,
we obtained gene-gene interaction data from protein-protein interaction databases as well as
signaling pathways to investigate the eﬀect of a variant on a subnetwork of genes.
Analyzing diﬀerent types of data made it clear that the characteristics and progression
of diﬀerent diseases are the results of the interaction between the disease and the immune
system of the host [12, 70, 97]. Because of this, diﬀerent patients may respond diﬀerently to
the same drug. Therefore, identifying diﬀerent subtypes of a given phenotype is extremely
important in selecting the most appropriate drug[35, 40].
We take advantage of data available in The Cancer Genome Atlas (TCGA) database [77].
TCGA is a collaboration between the National Cancer Institute (NCI) and National Human
Genome Research Institute (NHGRI), that includes data for 33 types of cancer covering many
dimensions of the genomic changes. This data includes 11,000 patients and is available for
research purposes.
The summary of data available in TCGA database is shown in Figure 1.1.
4Figure 1.1: Summary of diﬀerent cancer types available in TCGA database together with
the number of patients included [77].
5In this thesis, we focus on identifying the variants (with high or low frequencies) that
alter gene expression significantly for each individual. This is done by integrating mutation
and gene expression data, as well as a priori knowledge about gene-gene interaction networks
from multiple databases. We introduce an algorithm that divides the samples of one cancer
type into two subtypes by focusing on the variants that cause significant changes in gene
expression between the samples with and without those variants.
The groups of samples identified are validated by comparing the survival data for the
two groups. The survival analysis is widely used to validate the identified subtypes in a set
of patients [25, 37]. Survival analysis uses the measurements of the last follow-up time from
the beginning of treatment or diagnosis of a disease to time of death. Statistical tests are
performed to distinguish if there is any significant diﬀerence between the survival curves of
patients in those subtypes. Once the subtypes are identified, we investigate the diﬀerence
between them from a biological pathways context. The goal of pathway analysis methods is
to identify the most perturbed pathways in a given condition. Pathways are divided in two
main categories: i) signaling pathways, that are defined as graphs in which nodes represent
genes/proteins and edges are interactions between them, and ii) metabolic pathways in which
the nodes represent biochemical compounds and the edges represent reactions, carried out
by enzymes which are coded by genes [49]. A pathway describes all the known phenomena
involved in a given biological process, to which it is associated. It is part of a larger system
that has a set of components interacting with each other. These components work together
to achieve a common goal. The name of a pathway usually represents the biological process,
phenomenon, or disease process described by the pathway. Diﬀerent types of interactions
are described by diﬀerent types of edges, or weights in the structure of a pathway. As an
example, Figure 1.2 shows the apoptosis signaling pathway, which includes the genes and
interactions involved in the known mechanism for cell death. Diﬀerent types of interactions
are shown by diﬀerent arrows.
6Figure 1.2: KEGG apoptosis signaling pathway (from: http://www.genome.jp/kegg/
pathway/hsa/hsa04210.html).
Such pathways describe all known phenomena involved in a biological process (e.g.
cell cycle), or a disease (e.g. Alzheimer’s disease), etc. In this thesis, we focus on signaling
pathways to be able to map the measured expression level of the genes to the corresponding
nodes in those pathways. Intuitively, the impact of a given phenotype on a given pathway
should be determined by the number of diﬀerentially expressed (DE) genes on that pathway,
the magnitude of the changes in the expression level of the genes, and the type, direction
and strength of the interactions between the genes in that pathway.
The pathway databases, like KEGG [55], BioCarta [9] and Reactome [29], provide
complex graphs for each signaling pathway, in which each node is a gene/protein and each
edge is an interaction between two such genes or proteins. There are many methods that have
been proposed that are able to fully take into consideration all the interactions between genes
in signaling pathways to find which pathway is most impacted by a given phenotype [14].
These are sometimes referred to as “topology-aware” or “third generation” pathway analysis
methods [36, 49]. The method, used in this manuscript, is Impact Analysis, which belongs
7to this latest generation of pathway analysis methods, inasmuch as it considers the topology
of the pathways, as well as the changes in expression level of the genes [14]. The results
of pathways analysis can lead to better understanding of the mechanisms that cause the
diﬀerences between subtypes.
In summary, this thesis presents a novel method for identifying subtypes of a disease
by integrating variant and gene expression data. The method was validated on four diﬀerent
cancer types (renal, lung, colorectal cancer and leukemia) from the TCGA database. The
survival analysis shows significant diﬀerences between the identified subtypes in all the in-
vestigated diseases. To further understand the identified subtypes, we performed a pathway
analysis on the identified subtypes. We observed that the pathways that are significantly
perturbed between the subtypes are strongly known to be associated to each disease.
8Chapter 2
Methods
In this section, we propose a novel method that integrates gene expression and genetic
variant data to sub-type patients diagnosed with the same disease. The goal is to identify
those sub-groups that might share a common mechanism in order to be able to develop
novel drugs specific to each sub-group. First, we will introduce the method that integrates
variant and gene expression data to identify the subtypes. Then, we will describe the assess-
ment methods, survival and pathway analysis, used to quantify the quality of the subtypes
identified.
2.1 Subtype identification by integrating mutation and gene ex-
pression data
The method proposed here aims to detect variants that significantly aﬀect gene ex-
pression and use these variants to define novel sub-groups of patients. We start by focusing
on the gene in which each variant occurs. Henceforth, we will refer to this as the host gene.
We use gene expression data collected using either microarrays or RNA-Seq to identify if
there is an expression change between samples that have and do not have a given variant.
However, the expression of each gene evolves with time and because we collect data at a given
point in time, we might not get the full picture. To overcome this limitation, we decided
to enhance our search space and not only consider the eﬀect of a variant on its host gene,
but also the eﬀect of the variant on the genes that interact with its host gene. Hence, we
use a priori knowledge about gene-gene interactions obtained from diﬀerent protein-protein
interaction networks and available signaling pathways. We acquired the information from
9Human Protein database Reference (HPRD) (Release 9) [57, 58], BioGRID [73] and Kyoto
Encyclopedia of Genes and Genomes (KEGG) (Release 72.0) [30, 31, 32]. Using information
coming from these databases, we construct a “neighborhood” of each host gene that includes
all the genes that are directly connected to it in any of the considered interaction networks,
as well as the host gene itself.
For each dataset, we start by building a variant matrix, in which the rows represent
the existing variants in all the given samples, and columns represent the samples:
V AR =
0BBBBBBB@
var11 var12 ... var1p
var21 var22 ... var2p
... ... ... ...
varm1 varm2 ... varmp
1CCCCCCCA
where: varij = 1 if vari occurs in samplej, 0 otherwise. In this manuscript a variant refers
to a combination of a specific allele at a given position.
We then construct a gene expression matrix, in which the rows represent the host
genes for any variant in the variant matrix and their neighbors, and columns represent the
samples:
EXP =
0BBBBBBB@
exp11⇤ exp12⇤ ... exp1p⇤
exp21⇤ exp22⇤ ... exp2p⇤
... ... ... ...
expm1⇤ expq2⇤ ... expqp⇤
1CCCCCCCA
Here, expij⇤ is a vector including the expressions of the host genes and all the genes in the
neighborhood of the host gene for variant vari in samplej (see, Figure 2.1).
For all the variants that are present in a sample (all variants marked with red in
Figure 2.1), we compute a z-score for every gene expression associated with the variant
10
Figure 2.1: Expression values grouped by presence of variants: For each variant,
we consider the set of genes that belong to the neighborhood of the host genes. If
the variant is present in the given sample (marked with red), then we compute a
z-score for each gene and its neighborhood against all expressions in that row that
are not associated to the presence of the variant (marked with green). The values
in the blue box represent exp11⇤ from the EXP matrix.
association against all the expressions corresponding to samples not exhibiting the variant:
Z =
0BBBBBBB@
z11⇤ z12⇤ ... z1p⇤
z21⇤ z22⇤ ... z2p⇤
... ... ... ...
zm1⇤ zq2⇤ ... zqp⇤
1CCCCCCCA
where: zij⇤ is a vector including the z-scores of the host gene and all the genes in the
neighborhood of the host gene for variant vari calculated for samplej as follows:
zijk =
expijk  mean(expiMk)
sd(expiMk)
(2.1)
The zijk and expijk are the z-scores and expressions for the association between variant i and
the neighborhood of its host gene (gi1, gi2, ..., gik) in samplej, varij = 1, where variM = 0;
M 2 [1, p] (see Figure 2.1 and 2.2).
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Figure 2.2: Selecting significant variants based on z-score: If a variant is present
in a sample, we compute a z-score for every gene in its host gene’s neighborhood
(z-scores marked with red). We define a variant to be significant in a sample if any
of the z-scores computed for a gene in the host gene’s neighborhood is significant.
For example, we declare variant var1 to be significant in sample1 if any of the
z-scores in the blue box are significant (z11⇤ from Z matrix).
We define a variant to be significant in one sample if any of the genes in the host
gene’s neighborhood is significant at 1% in a two-tail testing framework (see Figure 2.3).
Hence, the resulting matrix will include the significant variants in each sample:
SIG V AR =
0BBBBBBB@
sig.var11 sig.var12 ... sig.var1p
sig.var21 sig.var22 ... sig.var2p
... ... ... ...
sig.varm1 sig.varm2 ... sig.varmp
1CCCCCCCA
where: sig.varij = 1 if vari is significant in samplej (i.e., if p-values associated to any of
the z-scores zij⇤ are less than 0.5% for either tail), 0 otherwise. Based on this significant
variant matrix, we define two subgroups based on the count of significant variants in each
sample. We define the high risk group as the one including the samples with larger number
of significant variants (more than the median) and the low risk group as the one including
the remaining samples (fewer variants than the median). We choose this separation with the
12
Figure 2.3: The two possible situations for a variant in a sample to be declared as
significant: The yellow nodes represent the variants identified in the sample. The
blue nodes are the host genes of the given variant and its neighbors. The orange
nodes are the genes with significant z-scores.
expectation that a large number of variants will produce a higher disruption and therefore
a lower survival rate.
2.2 Survival Analysis
Once we identified the subtypes, our goal is to assess if there is any diﬀerence in the
survival rates between the two groups. We use the well known Kaplan-Meier [33] estimator to
plot the survival curves based on lifetime data obtained from TCGA. The survival function,
S(t), is the probability of patients in a particular group to survive at the given time (t). The
probability of surviving in each period of time is a function of number patients alive at the
beginning of the period and the number of deaths in that period of time. The probability
of a patient to survive k or more periods depends on the survival rates in all the previous
periods [7].
S(t) = pi · p2 · p3 · ... · pk (2.2)
where:
pi =
number of alive patients at the beginning of period i - number of death in period i
number of alive patients at the beginning of period i
(2.3)
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Figure 2.4: An example of survival table available for a group of patients [7]. The table shows
the number of patients alive and number of death for each period of time. The probability
of survival is calculated for each period based on the survival rates in all the previous times.
The curve shows the probability calculated for each period. The censored patients are the
ones for whom the death event is not available due to the fact that they dropped out of the
study and the available data only shows their last follow-ups.
The method is explained with an example provided by [7] shown in Figure 2.4. We used the
R package survminer for plotting the survival curves of the two identified subtypes [34].
In addition, we compute the Cox p-value to assess if there is a diﬀerence between the
survival rates of the two groups.
2.3 Pathway Analysis
The subtypes identified are also validated using pathway analysis. We obtained all
the signaling pathways defined in the KEGG database [30, 31, 32]. We choose the Impact
Analysis (IA) [14] since it is the most widely used topology-based pathway analysis method.
This method takes into consideration the type and position of each gene, the magnitude of
expression change for each gene and the types of interactions between them. This was the first
14
proposed method that includes all the mentioned factors. Previous methods, only considered
the pathways as a set of genes and ignored all the interaction information that was provided
by the predefined pathways. We are using an extended version of IA that takes as input the
entire list of genes and it does not need a subset of genes as diﬀerentially expressed [88]. We
refer to this method as IA-all genes. The IA-all genes gives the opportunity to use the entire
set of measurements provided rather than just selecting a subset of them as diﬀerentially
expressed. Typically, the selection of DE genes will cause loss of data for more than 20,000-
30,000 genes, and the DE selection will only have information for about 300 genes. It was
shown that IA-all gene yields significantly better results compared to the classical IA [88].
In IA-all genes, the “perturbation factor” was calculated for all the genes in each pathway as
follows:
PF (gi) =  E(gi) +
X
u2USgi
 ugi · PF (u)
Nds(u)
(2.4)
where  E is the measured gene expression of the gene, US is a set of all the genes that
are upstream of the gene of interest (gi) in the predefined pathways, Nds is the number of
downstream genes for each of the genes upstream of the gene gi, and  ugi represent the type
of interaction between gene u and gi. In IA-all genes,  ugi = 1 if the type of interaction
is activation, or activation like and  ugi =  1 if the type of interaction is inhibition, or
inhibition like.
The score for pathway k is calculated as the sum of the absolute values of perturbation
factors of all the genes in the pathway, totalPF :
totalPFk =
X
i2pathwayk
|PF (gi)| (2.5)
The quantity totalPF of a pathway represents the amount of disruption of the whole
pathway in the condition under study. The significance of each pathway is assessed by
computing the probability of obtaining just by chance a totalPF value more extreme than
15
the one observed. This probability is estimated using a bootstrap approach, where the null
distribution for totalPF for each pathway is generated by sampling random gene expression
changes from the original set of expression changes. The number of bootstraps used was
2,000. This process is repeated for all pathways and yields a p-value for each pathway.
Subsequently, the set of p-values for all pathways are corrected for multiple comparisons
using the false discovery rate (FDR). Here, we used the ROntoTools version 2.0.0 , which is
an implementation of IA-all genes as an R package available in Bioconductor [89].
16
Chapter 3
Results
3.1 Lung Cancer
Lung cancer is one of the leading cause of death among all types of cancer [92].
According to American Lung association (http://www.lung.org/), a very small number of
patients (17.7 percent), diagnosed in very advanced stages, survive more than five years.
Lung squamous cell carcinoma is a very common subtype of lung cancer that causes more
than 400,000 deaths every year [79]. We use gene expression and mutation data for lung
squamous cell carcinoma (LUSC) from TCGA database [77] to subtype the cohort of patients
into two groups based on their molecular profile: short survival (more aggressive cancer)
and long term survival (less aggressive cancer). There are 178 LUSC patients that have
mutation profiles available, 154 LUSC patients that have gene expression profiles available,
and 89 patients that have both. Since the proposed method focuses on the integration of
gene expression with mutation data, we focus on the 89 patients that have both mutation
and gene expression profiles available for further analysis.
We pre-process the mutation data to include the variants that might have aﬀected
the gene expression and in turn the protein expression, which presumably determined the
phenotype. Out of the 29,565 variants that belong to at least one of the selected 89 patients,
we eliminate the silent mutations as these are unlikely to influence the phenotype. The
remaining 22,913 variants belong to 21 diﬀerent predicted classifications (frame shift, mis-
sense, non-sense, insertion of a stop codon, etc.). The gene expression data is pre-processed
to eliminate outliers, by considering only the genes that are expressed in more than 50% of
the samples. This reduces the number of genes considered from 12,042 to 11,883.
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To compute the neighborhood of each variant’s host gene, we obtained gene-gene
interaction information from KEGG [30, 31, 32], HPRD [57, 58] and BioGRID [73] databases.
The integrated network from these three sources includes 9,693 genes and 37,193 interactions.
Adding existing information about known interactions allows us to estimate the potential
eﬀect of a variant on groups of interacting genes.
For each variant in each sample, the z-scores for the host gene and its neighbors are
calculated as explained in the Methods section. The z-scores higher than 2.6, corresponding
to a p-value lower than 1%, are considered as significant. In each sample, we consider
the variants that cause a significant change in expression (significant z-scores) of its host
gene and/or its neighbors as significant variants (sig.vars). We divide the samples into two
groups based on the number of significant variants. The first group includes the samples
that have a number of significant variants higher than the median, while the second groups
includes samples with a number of significant variants lower than or equal to the median.
Our expectation is that the patients with higher number of significant variants will suﬀer of
an increase disruption and therefore have a lower survival rate.
We validate the identified subtypes in two ways. First, we use the information from
clinical data to perform a survival analysis. In this analysis, we compare the survival curves
of patients in the identified subtypes. Survival analysis aims to identify the proportion of the
population that survive during a given time [7]. To analyze the survival of the investigated
patients, we used the clinical data provided by TCGA. The survival time associated to each
patient is the time from beginning of their treatments until their deaths or their last follow-
ups. The state of dead/alive for the patients are also extracted from the clinical data. As
expected, the patients with higher number of significant variants exhibit a lower survival
rate than those with fewer (see red curve in Figure 3.1). The Cox p-value representing
the significance of diﬀerence between these two subtypes is 0.045. This significant p-value
validates that the molecular signature of the patients in two subtypes changes their survival
18
Figure 3.1: The survival curve of patients in the two identified subtypes in LUSC.
The red curve represents the patients with higher number of significant variants and
the blue curve represents the patients with a lower number of significant variants.
As expected the patients with higher number of significant variants have a lower
survival rate. The set of low survival patients contains 42 individuals while the other
contains 47. The Cox p-value representing the significance of diﬀerences between
two curves is 0.045.
rates. The subtypes could be investigated further to identify diﬀerent reactions to diﬀerent
drugs and could warrant more aggressive treatments to patients in the low survival group.
Second, we validate the subtypes by performing pathway analysis comparing the
patients in low versus high survival. Understanding the diﬀerences between the active mech-
anisms involved in each group helps to design better drugs and improve the knowledge of
the investigated disease. Pathway analysis results identify the networks that describe the
potential mechanisms that diﬀerentiate the two subtypes. The ranked list of pathways ac-
cording to the Impact Analysis [14, 88] is shown in Table 3.1. The top significant pathway,
chemokine signaling pathway has an important role in evolving many cancer diseases such
as non-small lung cancer [11, 76]. Also, interestingly we identified staphylococcus aureus
infection pathway as one of the top significant pathways. Staphylococcus aureus includes
mechanisms involved in diﬀerent types of infections such as superficial skin infections, food
poisoning and life-threatening infections [32]. There are many studies that show the impact
19
names totalPertNorm pPert pPert.fdr references
path:hsa04062 Chemokine signaling
pathway
6.52049 0.00050 0.01099 [11, 76]
path:hsa05150 Staphylococcus aureus
infection
5.79590 0.00050 0.01099 [60, 75]
path:hsa04512 ECM-receptor interac-
tion
5.30600 0.00050 0.01099 [42, 47]
path:hsa05144 Malaria 5.25846 0.00050 0.01099
path:hsa05323 Rheumatoid arthritis 5.15320 0.00050 0.01099 [27]
path:hsa04060 Cytokine-cytokine
receptor interaction
5.06846 0.00050 0.01099 [87]
path:hsa05146 Amoebiasis 4.69088 0.00050 0.01099
path:hsa04510 Focal adhesion 4.63666 0.00050 0.01099 [15, 42, 54]
path:hsa04080 Neuroactive ligand-
receptor interaction
-3.92057 0.00050 0.01099 [43]
path:hsa04145 Phagosome 4.76257 0.00099 0.01522
Table 3.1: The top 10 ranked pathways when comparing two subtypes from LUSC.
The highlighted pathways have strong associations with lung cancer based on lit-
erature.
of infection on survival of patients with lung cancer [60, 75]. Multiple studies show strong
association between the variants in ECM-receptor interaction pathway, which is one of the
top three significant pathways and risk for non-small cell lung cancer (LUSC) [42, 47]. In
summary, many of the top 10 significant pathways have known associations to lung cancer
(see Table 3.1).
Furthermore, as an alternative method of grouping the patients, we compare signifi-
cant variants with non-significant variants that share the same location in genome. In this
data, there are 6 such variants. We grouped the samples that contain the significant variants
in one group and samples containing the non-significant variants in the other. The list of the
variants, their position in the genome, and reference alleles are shown in Table 3.2. The sur-
vival analysis shows that the survival rate of patients with significant variants is drastically
aﬀected when comparing with those without (Figure 3.2).
Based on the assessments performed, our method is able to identify variants that
significantly aﬀect the gene expression, and therefore the phenotype. Patients with significant
variants, as defined by our method, generally have a lower survival rate.
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host gene chrom pos ref sig.var classification not sig.var classification
TP53 17 7577550 C - Frame Shift Del T Missense
TP53 17 7578177 C G Splice Site T Splice Site
TP53 17 7577538 C T Missense A Missense
TP53 17 7577538 C G Missense A Missense
TP53 17 7578458 G - Frame Shift Del C Missense
ARHGEF2 1 155921325 C T Splice Site A Splice Site
Table 3.2: Significant variants that share a position with non-significant variants in
LUSC: For each significant variant (red), we show the host gene and the associated
non-significant variant (blue). For each variant, we include the associated classifi-
cation. Notice that even variants with same classification have diﬀerent eﬀect on
gene expression.
Figure 3.2: The survival curve of patients with significant variants (red) compared
to patients that have a non-significant variants (blue) at the same location in LUSC.
The Cox p-value (0.035) shows there is a significant diﬀerence between the survival
rates.
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3.2 Kidney Cancer
We analyzed data that come from experiments studying renal cell carcinoma (KIRC),
which is the most common type of kidney cancer [44]. This type of cancer can easily spread
to other organs such as lungs. In most of the patients, the cancer has already spread when
the cancer is diagnosed and the survival of the patients highly depends on the spread of the
cancer. We downloaded the gene expression and variant data from TCGA database. The
gene expression data includes measurements for 533 patients and the variant data includes
profiles of 417 patients. We focus on 324 patients for whom both types of data are available.
The pre-processing of variant data by eliminating silent variants and variants that do not
appear in the 324 patients resulted in 40,211 variants.
The gene expression data is pre-processed as well by removing any gene that did not
have measurements in at least half the samples. This resulted in 13,002 genes to be used
further in the analysis. The same gene-gene interactions downloaded from KEGG, HPRD
and BioGRID are used here, as well.
After the subtyping, the group with expected low survival (i.e., number of significant
variants more than the median) exhibited an even more significant diﬀerence than the lung
cancer comparison. The Cox p-value representing the significance of diﬀerence between two
curves is 0.0067 (see Figure 3.3).
The top significant pathways resulted from the pathway analysis are known to be
associated to kidney cancer, which further validates the identified subtypes (see Table 3.3).
The rap1 signaling pathway, which is the top significant pathway found by our method, is
also identified as the most perturbed pathway by independent researchers [51]. This is a
validation of the involvement of this pathway in progression of kidney cancer. Most of the
top pathways include mechanisms that have the potential to explain diﬀerent survival of
samples in kidney cancer.
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Figure 3.3: The survival curve of patients in the two identified subtypes in KIRC.
The red curve represents the patients with higher number of significant variants and
the blue curve represents the patients with a lower number of significant variants.
As expected the patients with higher number of significant variants have a lower
survival rate. The set of low survival patients contains 154 individuals while the
other contains 170. The Cox p-value representing the significance of diﬀerences
between two curves is 0.0067.
names totalPertNorm pPert pPert.fdr
path:hsa04015 Rap1 signaling pathway 8.77739 0.00050 0.00275 [51]
path:hsa04151 PI3K-Akt signaling
pathway
8.54322 0.00050 0.00275 [4, 21]
path:hsa04080 Neuroactive ligand-
receptor interaction
7.99071 0.00050 0.00275 [44, 96]
path:hsa04060 Cytokine-cytokine
receptor interaction
7.23171 0.00050 0.00275 [28, 56]
path:hsa04510 Focal adhesion 7.15629 0.00050 0.00275 [66]
path:hsa04614 Renin-angiotensin sys-
tem
6.65325 0.00050 0.00275 [48, 50]
path:hsa04014 Ras signaling pathway 6.03074 0.00050 0.00275 [4]
path:hsa04022 cGMP-PKG signaling
pathway
5.78521 0.00050 0.00275
path:hsa05166 HTLV-I infection 5.77079 0.00050 0.00275
path:hsa04066 HIF-1 signaling path-
way
5.74182 0.00050 0.00275 [68]
Table 3.3: The top 10 ranked pathways when comparing two subtypes from KIRC.
The highlighted pathways have strong associations with kidney cancer based on
literature.
23
host gene chrom pos ref sig.var classification not sig.var classification
PIK3CA 3 178952085 A G Missense T Missense
TCEB1 8 74858968 T C Missense A Missense
VHL 3 10183794 G T Missense A Nonsense
VHL 3 10191470 G A Splice Site T Splice Site
VHL 3 10191470 G C Splice Site T Splice Site
VHL 3 10191480 T C Missense - Frame Shift Del
VHL 3 10191480 T G Missense A Missense
VHL 3 10191570 T G Missense C Missense
Table 3.4: Significant variants that share a position with non-significant variants in
KIRC: For each significant variant (red), we show the host gene and the associated
non-significant variant (blue). For each variant, we include the associated classifi-
cation. Notice that even variants with same classification have diﬀerent eﬀect on
gene expression.
When comparing significant variants with non-significant ones that share the same
location (see Table 3.4), the survival comparison exhibits significant diﬀerence between the
groups with a p-value of 0.011 (see Figure 3.4).
Overall, the renal cancer study confirms as well that having a large number of signif-
icant variants, as defined by our method, implies a lower survival rate.
3.3 Colorectal Cancer
The colorectal cancer generally occurs in the colon or rectum, which are parts of the
digestive system. Colorectal adenocarcinoma is the most common colorectal cancer that
often begins with a polyp growth formed on the inner part of the colon [20]. Colorectal
cancer is the fourth common cancer, however the survival rate has improved due to early
detection through colonoscopies and blood tests [72]. The gene expression data including 457
samples, and variant data including 154 samples studying colon adenocarcinoma (COAD) are
downloaded from TCGA database. The analysis is performed on 137 number of samples for
whom both types of data is available. After removing the variants with silent classification,
the variant data includes 41,115 variants.
The gene expression data includes measurements for 17,062 genes. We removed the
genes that do not have any expression for more than 50% of the samples. The number of
genes that satisfies this condition is 12,387. The samples, as explained before, are divided
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Figure 3.4: The survival curve of patients with significant variants (red) compared
to patients that have a non-significant variants (blue) at the same location in KIRC.
The Cox p-value (0.011) shows there is a significant diﬀerence between the survival
rates.
in two groups based on the number of significant variants. The survival rate of each group
is shown in Figure 3.5. The calculated cox p-value (0.024) indicates that the survival rates
of two identified groups are significantly diﬀerent.
Same as before, we validate the identified groups by performing pathway analysis
comparing the gene expression in each group. The results in Table 3.5 show that the ranked
list of significant pathway are strongly associated to colorectal cancer. The results in [52]
indicate that there are significant changes in renin-angiotensin system, which is the top
significant pathway by our method, in colorectal cancer metastases. Neo et. al suggest that
a blockade of the renin-angiotensin system decreased tumor growth in colorectal cancer.
This pathway is significantly perturbed when comparing one identified subtype versus the
other. Many of the top ten pathways, resulted from our method, have known associations to
colorectal cancer based on literature and they include the mechanisms that have potential
to explain the diﬀerences between the survival of diﬀerent samples in each group.
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Figure 3.5: The survival curve of patients in the two identified subtypes in COAD.
The red curve represents the patients with higher number of significant variants and
the blue curve represents the patients with a lower number of significant variants.
As expected the patients with higher number of significant variants have a lower
survival rate. The set of low survival patients contains 62 individuals while the other
contains 75. The Cox p-value representing the significance of diﬀerences between
two curves is 0.024.
names totalPertNorm pPert pPert.fdr references
path:hsa04614 Renin-angiotensin system 4.23970 0.00100 0.09895 [2, 52]
path:hsa04978 Mineral absorption 3.61844 0.00100 0.09895 [59, 98]
path:hsa04972 Pancreatic secretion 4.53224 0.00150 0.09895
path:hsa04310 Wnt signaling pathway 3.69741 0.00300 0.11309 [8, 53, 63]
path:hsa04260 Cardiac muscle contraction -3.16972 0.00300 0.11309
path:hsa04918 Thyroid hormone synthesis 3.14207 0.00350 0.11309
path:hsa04976 Bile secretion 3.27800 0.00400 0.11309 [62, 22]
path:hsa03320 PPAR signaling pathway 2.96947 0.00500 0.12369 [95]
path:hsa04145 Phagosome -2.63990 0.00600 0.13193
path:hsa05012 Parkinson’s disease -2.59650 0.00700 0.13853
Table 3.5: The significant pathways when comparing two subtypes from COAD.
The highlighted pathways have strong associations with colorectal cancer based on
literature.
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host gene chrom pos ref sig.var classification not sig.var classification
FBXW7 4 153247289 G A Missense C Missense
KRAS 12 25398284 C A Missense G Missense
KRAS 12 25398284 C T Missense G Missense
PIK3CA 3 178936091 C A Missense C Missense
NRAS 1 115258747 C T Missense G Missense
Table 3.6: Significant variants that share a position with non-significant variants
in COAD: For each significant variant (red), we show the host gene and the asso-
ciated non-significant variant (blue). For each variant, we include the associated
classification. Note that even variants with same classification have diﬀerent eﬀect
on gene expression.
We analyzed the significant variants that share the chromosomal position with non-
significant variants (see Table 3.6). The subtypes are identified by samples with such signifi-
cant variants and samples with non-significant variants at the same position. The Figure 3.6
shows the survival rates of the two subtypes. The p-value is not significant, which maybe
due to the low number (4) of samples that are associated to the non-significant variant.
3.4 Acute Myeloid Leukemia
Acute Myeloid Leukemia (LAML) is the most common type of acute leukemia. It is
caused by an increase in the number of myeloid cells, which have not matured. These cells will
not develop and will not be able to prevent infections. Recently, with diagnosis of subtypes
of LAML, and improvements of drug treatments the survival rates have increased [46]. The
gene expression data for LAML from TCGA includes 179 samples, while the variant data
includes 197. The number of common samples with both data types is 162. After removing
the variants with silent predicted classification, the variant data includes 1,618 number of
variants.
The gene expression includes measurements for 16,818 genes and after filtering the
genes without any expression in more than 50% of the samples the data includes 12,204
genes. The samples are divided in two subtypes as explained before. The survival rates of
the two subtypes are shown in Figure 3.7. The significant Cox p-value indicates significant
diﬀerences between the survival rates meaning that the identified subtypes are meaningful.
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Figure 3.6: The survival curve of patients with significant variants (red) com-
pared to patients that have a non-significant variants (blue) at the same location in
COAD. The survival curves shows there is a diﬀerence between the survival rates
even though the p-value is not significant.
Figure 3.7: The survival curve of patients in the two identified subtypes in LAML.
The red curve represents the patients with higher number of significant variants and
the blue curve represents the patients with a lower number of significant variants.
As expected the patients with higher number of significant variants have a lower
survival rate. The set of low survival patients contains 73 individuals while the
other contains 89. The Cox p-value representing the significance of the diﬀerences
between two curves is 0.039.
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The results of pathway analysis are shown in Table 3.7. The references mentioned in
the table show that the significant pathways are associated to acute myeloid leukemia. An
independent study of acute myeloid leukemia [17] has also identified the neuroactive ligand-
receptor interaction pathway to be significantly perturbed (with p-value 10 5). This is the
second top significant pathway resulted from our method.
names totalPertNorm pPert pPert.fdr references
path:hsa05144 Malaria 10.13814 0.00050 0.00660
path:hsa04080 Neuroactive ligand-
receptor interaction
9.40327 0.00050 0.00660 [17]
path:hsa04610 Complement and coagu-
lation cascades
9.13439 0.00050 0.00660
path:hsa05134 Legionellosis 8.62989 0.00050 0.00660 [67]
path:hsa05322 Systemic lupus erythe-
matosus
8.54986 0.00050 0.00660 [86]
path:hsa05150 Staphylococcus aureus
infection
7.85037 0.00050 0.00660 [41]
path:hsa04060 Cytokine-cytokine
receptor interaction
7.15228 0.00050 0.00660 [94]
path:hsa05202 Transcriptional misreg-
ulation in cancer
6.92006 0.00050 0.00660
path:hsa05140 Leishmaniasis 6.51377 0.00050 0.00660
path:hsa04620 Toll-like receptor signal-
ing pathway
6.24701 0.00050 0.00660 [71]
Table 3.7: The top 10 ranked pathways when comparing two subtypes from LAML.
The highlighted pathways have strong associations with kidney cancer based on
literature.
Same as all previous studies, we analyzed the significant variants that share a position
with non-significant variants with diﬀerent alleles. The list of such variants, their position
in the genome, and reference alleles are shown in Table 3.8. The survival curves of patients
with these variants are shown in Figure 3.8.
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host gene chrom pos ref sig.var classification not sig.var classification
DNMT3A 2 25457242 C T Missense G Missense
IDH1 2 209113113 G A Missense T Missense
U2AF1 2 ,44524456 G T Missense A Missense
Table 3.8: Significant variants that share a position with non-significant variants in
LAML: For each significant variant (red), we show the host gene and the associated
non-significant variant (blue). For each variant, we include the associated classifi-
cation. Notice that even variants with same classification have diﬀerent eﬀect on
gene expression.
Figure 3.8: The survival curve of patients with significant variants (red) compared
to patients that have a non-significant variants (blue) at the same location in LAML.
The survival curves shows there is a diﬀerence between the survival rates even
though the p-value is not significant.
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Chapter 4
Discussion and conclusions
We proposed a novel method that integrates multiple types of data to subtype patients
diagnosed with the same disease. The goal was to identify those subgroups that share the
same mechanisms and the same molecular profile in order to be able to develop novel drugs
specific to each subgroup. We showed the eﬀectiveness of the method on four of the most
common cancer types (renal, lung, colorectal cancer and leukemia) using data from the The
Cancer Genome Atlas (TCGA). The survival analysis between the groups identified showed
a significant diﬀerences in the survival rates in all four patient cohorts studied. In addition,
by comparing the long term versus the short term survival groups using pathway analysis,
we identified that the top pathways in each study are strongly associated in literature with
the conditions under study.
One of the main challenges when studying cancer samples is the heterogeneity of the
molecular profiles even within the same phenotype. This aspect was clear from the begin-
ning of our study when we compared the number of samples that share each variant (see
Figure 4.1). In best case scenario the percentage of samples that share a variant ranges
from 5.6% to 15% in the samples considered. On average this is much worse, with percent-
ages ranging from 0.03% to 1%. Even with this limitation, our method is able to extract
information from each variant and increase the power of the analysis by integrating gene
expression.
In the proposed method, the main diﬀerentiator between the groups identified is the
number of significant variants in each sample. It is only natural to ask the question if this
method is biased towards patients with more variants. In other words, perhaps our results
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(a) LUSC (b) KIRC
(c) COAD (d) LAML
Figure 4.1: The number of samples having a given variant. In most of the cases,
each variant only occurs in one sample. The maximum numbers of samples in
LUSC, KIRC, COAD and LAML are 5, 26, 21 and 19, respectively.
showing that one of the subgroups has a significantly shorter survival may be due to the fact
that those patients simply have much more mutations or genetic instability. To investigate
this, we assumed that the number of variants (as obtained from TCGA) is the diﬀerentiator.
We grouped the patients that have more than the median number of variants and fewer
than the median in each one of the investigated diseases. We performed the same survival
analysis and none of the pairs of groups chosen this way were significant (see Figure 4.2).
This confirms that the number of variants alone cannot divide the patients in significantly
diﬀerent groups. In other words, the shorter survival of the groups we identified is not simply
due to the presence of more mutations.
In summary, here we proposed a novel method for integrating gene expression and
variant data with the purpose of subtyping patients in long and short term survival. Based
on our study of four of the most common cancer types, the proposed method is able to split
in subgroups each study cohort with significant diﬀerences in rate of survival.
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(a) LUSC (b) KIRC
(c) COAD (d) LAML
Figure 4.2: Survival rates of identified groups based on the number of variants in
the samples. The survival curves show that the rates in divided groups are not
significant.
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